Every medtech founder hits this fork in the road, usually sometime between their second prototype and their first serious funding round. Do you license a white-label platform, customize it to your needs, and get to market faster? Or do you build your own software from the ground up, own every line of code, and control your destiny?

Pick wrong, and you’ll burn through 12 to 18 months of runway fixing the mistake. Pick right, and you set the foundation for everything that comes after: your regulatory path, your margins, your ability to raise follow-on capital, and eventually your exit valuation.

This isn’t a theoretical exercise. It’s the single most consequential technical decision your startup will make in year one.

The Real Trade-Off Nobody Explains Clearly Enough

Most articles frame this as a simple cost-versus-control comparison. That’s too shallow. The buy-or-build question touches five distinct areas, and you need to evaluate all of them before you commit.

1. Regulatory pathway. If you’re building Software as a Medical Device (SaMD), your software lifecycle must comply with IEC 62304, the international standard governing medical device software development processes. Platforms that already carry regulatory documentation can shave months off your submission timeline. But here’s the catch: the FDA holds you responsible for the final product regardless of who built the components. According to the FDA’s 2023 guidance on cybersecurity in medical devices, manufacturers must provide a Software Bill of Materials (SBOM) and demonstrate ongoing vulnerability management. If your platform vendor won’t share their SBOM or update cadence, you’re inheriting risk you can’t control.

2. Speed to market. A platform can cut your initial development time by 40% to 60%, depending on how closely it matches your use case. That matters when you consider that the median 510(k) review time was 124 calendar days in fiscal year 2023, according to FDA performance data. Every month you save before submission is a month closer to revenue.

3. Long-term unit economics. Platform licensing fees compound. A typical per-device or per-user SaaS model might look affordable at 500 users but becomes your largest cost center at 50,000. Custom-built software has higher upfront costs but near-zero marginal cost per user.

4. Intellectual property ownership. If your exit strategy involves acquisition, buyers pay a premium for proprietary technology. McKinsey’s 2022 analysis of medtech M&A showed that companies with defensible IP commanded valuation multiples 1.5x to 2.5x higher than those built on third-party platforms.

5. Clinical differentiation. If your competitive advantage lives in the software (a unique algorithm, a novel data visualization, a proprietary clinical workflow), building from scratch is almost always the right call. Platforms are designed for the general case. Your edge comes from the specific case.

When Buying a Platform Actually Makes Sense

Not every startup needs to build from scratch, and plenty of successful medtech companies launched on commercial platforms before transitioning later. The key is knowing whether your situation fits.

Buying works best when your core innovation lives in the hardware or the clinical application, not in the software itself. If your device collects a new type of biometric data and the software just needs to display it, store it, and transmit it securely, a platform handles that well. You’re not competing on software; you’re competing on what the device measures.

It also works when speed is existential. If you have 10 months of runway and need clinical data to raise your Series A, spending 7 of those months on custom architecture is a gamble you might not survive. A platform gets you collecting data faster, and data is what investors want to see.

Here are the scenarios where a platform approach tends to pay off:

• Your software requirements closely match an existing commercial platform’s core functionality (80% or more overlap).
• The software is a supporting component, not the core differentiator of your device.
• You’re pre-seed or seed-stage with less than 12 months of runway and need clinical validation data quickly.
• Your regulatory strategy benefits from using a platform with existing FDA documentation and compliance history.
• You plan to transition to custom software after securing Series A or B funding, and the platform’s architecture allows data migration.

The risk? Lock-in. Most medical device platforms use proprietary data formats and APIs. Migrating away later can cost as much as building from scratch would have in the first place. That’s why some founders start on a platform but work with a medical device software development company from the outset to architect the transition plan, ensuring data portability and regulatory continuity when the switch happens.

Before you sign a platform contract, ask three questions: Can I export all patient and device data in standard formats (HL7 FHIR, CSV, JSON)? What happens to my data if the vendor shuts down? And does my contract allow me to modify or extend the platform’s FDA-related documentation?

If the answers are vague, walk away.

When Building From Scratch Is Worth the Investment

Custom development is more expensive upfront and takes longer. That’s the trade-off, and it’s real. But for certain startups, it’s the only option that doesn’t create problems down the road.

Building makes sense when the software is the product. If you’re developing an AI-powered diagnostic tool, a predictive analytics engine for patient monitoring, or a clinical decision support system, your algorithms and data pipelines are your competitive moat. Licensing someone else’s framework to house your proprietary intelligence is like building a racing engine and dropping it into a rental car.

It also makes sense when you’re targeting a regulatory pathway where control over every software component matters. The FDA’s De Novo classification pathway, used for novel devices without a predicate, requires extensive documentation of your software’s design, verification, and validation. Partnering with a team that understands IEC 62304 compliance from day one can prevent the kind of documentation gaps that trigger FDA additional information requests and add months to your review timeline.

Consider building from scratch when these conditions apply:

1. Your core competitive advantage is a proprietary algorithm, data model, or clinical workflow embedded in the software.
2. You need full control over the software architecture to meet specific regulatory requirements (particularly for Class II or Class III devices).
3. Your long-term business model depends on per-device margins that platform licensing fees would erode at scale.
4. You’re pursuing a De Novo or PMA pathway where complete software lifecycle documentation (per IEC 62304) is non-negotiable.
5. Your exit strategy depends on demonstrating proprietary technology to potential acquirers.

The biggest mistake founders make with custom builds isn’t the decision itself. It’s underestimating the compliance workload. A 2021 study published in the Journal of Medical Internet Research found that regulatory and compliance activities consumed 30% to 40% of total development time for digital health products. If your budget and timeline don’t account for that, you’ll either blow past your deadlines or cut corners that come back to bite you during FDA review.

The Hybrid Path That Most Smart Founders Actually Take

Here’s what rarely gets discussed: you don’t have to pick one approach and commit forever. The most capital-efficient strategy for many medtech startups is a phased hybrid model.

Phase one: use a compliant commercial platform (or open-source framework with regulatory documentation) for your non-differentiating features. Patient data storage, user authentication, basic device connectivity, audit logging. These are solved problems. Don’t re-solve them.

Phase two: build your proprietary components custom. Your diagnostic algorithm, your unique clinical interface, your data analytics engine. These sit on top of or alongside the platform layer and contain your actual IP.

Phase three: as you scale past product-market fit, selectively replace platform components with custom ones where the economics justify it. This is where your per-unit margins improve and your technology stack becomes fully yours.

This approach works because it matches your spending to your stage:

1. Pre-revenue, you minimize burn by buying commodity components.
2. Post-funding, you invest in the custom pieces that drive clinical and competitive differentiation.
3. Post-product-market-fit, you optimize unit economics by replacing licensed components with owned ones.

Spotify followed a similar playbook outside of healthcare. They launched on third-party infrastructure, built their core recommendation engine in-house from day one, and gradually replaced commodity components as they scaled. The principle transfers directly: own what differentiates you, rent what doesn’t.

Three Questions to Pressure-Test Your Decision

Before you commit either way, run your situation through these filters:

Where does your IP live? If a competitor could license the same platform and replicate 80% of your product, you don’t have a defensible business. You have a feature on someone else’s technology. Build your differentiators custom.

What’s your 18-month cash position? Custom development for a regulated medical device typically runs $500K to $2M for an MVP, depending on complexity and classification. If your funding doesn’t cover that plus 6 months of buffer, a platform-first approach keeps you alive long enough to raise more.

Who’s your acquirer? If your exit strategy targets a large medtech company (Medtronic, Abbott, Philips), they’re buying your IP and your clinical data. They already have platforms. If your exit targets a platform company, they’re buying your customer base. Know which story you’re telling, and build the technology stack that supports it.

The Decision That Compounds

This choice ripples through every subsequent decision your startup makes. It determines who you hire, how you structure your quality management system, what your gross margins look like at scale, and how attractive you are to acquirers.

There’s no universally correct answer. But there is a universally correct process: be honest about where your value lives, realistic about your runway, and deliberate about what you own versus what you rent.

The founders who get this right aren’t the ones who pick the cheapest option or the fastest one. They’re the ones who pick the option that matches their actual competitive advantage and regulatory reality. Everything else is noise.